巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Enanta Pharmaceuticals

    ENTA
    39.270
    3.100
    7.32%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Enanta Pharmaceuticals - 延遲價格・最後更新於 24/05 8:25
    最高位
    41.610
    最低位
    38.910
    開市價
    --
    前收市價
    42.370
    成交量(千)
    13.17
    成交額(百萬)
    4.32
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    813.39
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    102.000 - 38.020
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Enanta Pharmaceuticals
    證券代碼
    ENTA.US
    所屬板塊
    Biotechnology
    公司業務
    Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
    發行量
    20214850
    公司總部
    500 Arsenal Street
    公司網址
    http://www.enanta.com
    公司電郵
    jviera@enanta.com
    公司電話
    +1 617 607-0800
    暫無內容

    關於

    Enanta Pharmaceuticals(ENTA.US)所屬的行業板塊為Biotechnology。
    Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
    詳細公司背景可參考: http://www.enanta.com